Literature DB >> 35443600

Hematologic Evaluation of Children with COVID-19 Infection: Mortality Biomarkers.

Ali Aminasnafi, Solmaz Heidari, Mohsen Alisamir, Mohammadreza Mirkarimi, Najmeh Namehgoshayfard, Seyed M S Pezeshki.   

Abstract

BACKGROUND: In this study, we investigated the predictive value of routine coagulation parameters including D-dimer, Prothrombin Time (PT), International Normalized Ratio (INR), activated Partial Thromboplastin Time (aPTT) and Complete Blood Count (CBC) test parameters in children with COVID-19 infection.
METHODS: Retrospective and observational study carried out in Abuzar Hospital, Ahvaz Jundishapur University of Medical Sciences (Ahvaz, Iran) included COVID-19 patients.
RESULTS: Deceased patients (n = 5) compared to alive patients (n = 76) showed higher RDW (p = 0.005), PT (p = 0.005), INR (p = 0.004), PTT (p = 0.009), platelet count (p < 0.001), PLR (p < 0.001), and hospitalization time (p < 0.001). The area under the curve (AUC) of RDW was 0.85 (95% CI 0.75 - 0.96) which indicates its high power for mortality prediction in hospitalized children with COVID-19. We did not find significant differences in parameters in comparison between different severities.
CONCLUSIONS: To our knowledge, our study is one of the few studies to evaluate routine coagulation tests and the CBC test parameters predictive value in children with COVID-19. RDW has the most power to predict the mortality of children with COVID-19, followed by PT, INR, aPTT, platelet count, PLR, and hospitalization time have a high power to predict the risk of death in patients.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35443600     DOI: 10.7754/Clin.Lab.2021.210746

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  1 in total

1.  Predicting mortality in hospitalized COVID-19 patients.

Authors:  Amedeo Tirandi; Davide Ramoni; Fabrizio Montecucco; Luca Liberale
Journal:  Intern Emerg Med       Date:  2022-06-15       Impact factor: 5.472

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.